Skip to main content
Solasia Pharma K.K. logo

Solasia Pharma K.K. — Investor Relations & Filings

Ticker · 4597 ISIN · JP3436500007 LEI · 529900A8W8K4LULTG564 T Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2026-03-24 Regulatory Filings
Country JP Japan
Listing T 4597

About Solasia Pharma K.K.

https://solasia.co.jp/en/

Solasia Pharma K.K. is a specialty pharmaceutical company focused on oncology. The company's business model involves in-licensing promising drug candidates to develop and commercialize them for patients in Asian markets. Its portfolio is centered on addressing unmet medical needs in both cancer treatment and supportive care, aiming to improve patients' quality of life. Key commercialized products include Sancuso® for chemotherapy-induced nausea and vomiting (CINV), DARVIAS® for peripheral T-cell lymphoma (PTCL), and episil® oral liquid, a medical device for pain associated with oral mucositis. The development pipeline includes candidates for treating chemotherapy-induced peripheral neuropathy (CIPN) and colorectal cancer.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1. It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report, should be classified as Regulatory Filings (RNS) rather than the report itself. FY 2025
2026-03-24 Japanese
有価証券報告書－第18期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuuka Shouken Houkokusho' (Annual Securities Report), which is the Japanese equivalent of a 10-K. It contains detailed financial statements, management indicators, and corporate information for the fiscal year ending December 31, 2025. It is a comprehensive annual filing submitted to the Kanto Local Finance Bureau, not an announcement or a summary. FY 2025
2026-03-24 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-5-2 of the Financial Instruments and Exchange Act of Japan. This specific document is a mandatory attachment to the Interim/Quarterly Report (Hankishohokokusho) in Japan, where management confirms the accuracy of the financial statements. Since it is a regulatory filing confirming the contents of a report rather than the report itself, and it does not fit into the other specific categories like '10-K' or 'IR', it is classified as a Regulatory Filing.
2025-08-13 Japanese
半期報告書－第18期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) for Solasia Pharma K.K. for the period ending June 30, 2025. It contains detailed financial statements, management analysis (MDA), and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-13 Japanese
訂正有価証券届出書（組込方式）
Capital/Financing Update Classification · 98% confidence The document is titled "訂正有価証券届出書（組込）" which translates to "Amended Securities Registration Statement (Inline XBRL)". It is filed with the Kanto Local Finance Bureau ("関東財務局長") and dated March 24, 2025. The subject matter explicitly details the terms for the issuance of new stock acquisition rights ("新株予約権証券"), including offering conditions, exercise prices, capital structure adjustments, and the intended use of proceeds for drug development. This content aligns perfectly with the regulatory filing requirements for offering securities, specifically a registration statement related to capital raising activities. In the provided definitions, the closest fit for a comprehensive securities registration document detailing a capital change (issuance of stock acquisition rights) is related to financing or capital structure changes. While it involves capital ("CAP"), the document itself is a formal regulatory filing for the issuance of securities. In the context of Japanese financial filings, a Securities Registration Statement (有価証券届出書) is a core regulatory disclosure. Given the options, and recognizing this as a formal filing detailing a capital/financing event (issuance of stock acquisition rights), the most appropriate classification is related to Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). However, since the document is the actual registration statement detailing the terms of the offering (not just an announcement of the report's publication), and it is fundamentally about raising capital via stock options, 'CAP' is a strong candidate. If a specific registration statement code like 'S-1' or 'F-1' were available, that would be preferred. Given the provided list, and the focus on the terms of the new security issuance for fundraising, 'CAP' (Capital/Financing Update) is highly relevant, but 'RNS' (Regulatory Filings) is the standard fallback for specific regulatory documents not explicitly listed. Since the document is a detailed registration statement for a new security issuance (stock acquisition rights), it is a primary regulatory disclosure concerning capital raising. I will classify it as 'CAP' due to the explicit focus on fundraising terms, but acknowledge its nature as a formal regulatory filing. Given the detailed nature and the explicit focus on the terms of the new security issuance for fundraising, 'CAP' is the most descriptive category among the choices for the *content*. Revisiting the definitions: 'CAP' is for 'Updates on company fundraising, financing activities, or capital structure changes.' This document is the core filing detailing such an activity (issuance of stock acquisition rights for fundraising). 'RNS' is a general regulatory announcement fallback. Since the content is highly specific to financing terms, 'CAP' is chosen over the general 'RNS'.
2025-03-31 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director. Section 1 explicitly states the reason for filing: '2025年３月26日開催の当社第17回定時株主総会において、決議事項が決議されましたので...本臨時報告書を提出するものです' (Because resolutions were passed at our 17th Annual General Meeting held on March 26, 2025... this Extraordinary Report is being submitted). Section 2 details the resolutions passed, which include the election of directors and auditors, and a capital reduction. The content is a formal report detailing the results of a shareholder meeting (AGM). While it relates to the AGM, the filing itself is a regulatory disclosure of the voting results and resolutions passed at that meeting. This aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA), as it specifically reports the outcome of shareholder votes on resolutions, which is a key component of DVA, rather than general AGM presentation materials (AGM-R). Given the formal regulatory structure (Extraordinary Report detailing voting results), DVA is the most precise fit.
2025-03-31 Japanese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.